Literature DB >> 19306601

Cytomegalovirus vaccines: at last, a major step forward.

Mark R Schleiss1.   

Abstract

Yow and Demmler published an editorial in 1992 entitled Congenital cytomegalovirus disease--20 years is long enough. This editorial pointed out that, despite the long-standing recognition of the major public health importance of congenital human cytomegalovirus (CMV) infection, few solutions had been forthcoming. In no area has the lack of progress been more frustrating than in the realm of CMV vaccine development. Although a number of vaccine strategies have been considered, few have advanced to the stage of efficacy testing.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19306601      PMCID: PMC4385584     

Source DB:  PubMed          Journal:  Herpes        ISSN: 0969-7667


  10 in total

Review 1.  Vaccination against cytomegalovirus, the changeling demon.

Authors:  S A Plotkin
Journal:  Pediatr Infect Dis J       Date:  1999-04       Impact factor: 2.129

2.  Congenital cytomegalovirus disease--20 years is long enough.

Authors:  M D Yow; G J Demmler
Journal:  N Engl J Med       Date:  1992-03-05       Impact factor: 91.245

3.  Safety and immunogenicity of Towne cytomegalovirus vaccine with or without adjuvant recombinant interleukin-12.

Authors:  Mark A Jacobson; Elizabeth Sinclair; Barry Bredt; Laurie Agrillo; Douglas Black; C Lorrie Epling; Alexander Carvidi; Terence Ho; Raji Bains; Valerie Girling; Stuart P Adler
Journal:  Vaccine       Date:  2006-05-02       Impact factor: 3.641

4.  Development and preclinical evaluation of an alphavirus replicon particle vaccine for cytomegalovirus.

Authors:  Elizabeth A Reap; John Morris; Sergey A Dryga; Maureen Maughan; Todd Talarico; Robert E Esch; Sarah Negri; Bruce Burnett; Andrew Graham; Robert A Olmsted; Jeffrey D Chulay
Journal:  Vaccine       Date:  2007-08-30       Impact factor: 3.641

5.  Safety and immunogenicity of a bivalent cytomegalovirus DNA vaccine in healthy adult subjects.

Authors:  Mary K Wloch; Larry R Smith; Souphaphone Boutsaboualoy; Luane Reyes; Christina Han; Jackie Kehler; Heather D Smith; Linda Selk; Ryotaro Nakamura; Janice M Brown; Thomas Marbury; Anna Wald; Alain Rolland; David Kaslow; Thomas Evans; Michael Boeckh
Journal:  J Infect Dis       Date:  2008-06-15       Impact factor: 5.226

6.  Attenuated poxvirus expressing three immunodominant CMV antigens as a vaccine strategy for CMV infection.

Authors:  Zhongde Wang; Corinna La Rosa; Simon F Lacey; Rebecca Maas; Shahram Mekhoubad; William J Britt; Don J Diamond
Journal:  J Clin Virol       Date:  2006-01-04       Impact factor: 3.168

Review 7.  Progress toward an elusive goal: current status of cytomegalovirus vaccines.

Authors:  Mark R Schleiss; Thomas C Heineman
Journal:  Expert Rev Vaccines       Date:  2005-06       Impact factor: 5.217

8.  A phase 1 study of 4 live, recombinant human cytomegalovirus Towne/Toledo chimeric vaccines.

Authors:  Thomas C Heineman; Mark Schleiss; David I Bernstein; Richard R Spaete; Lihan Yan; Greg Duke; Mark Prichard; Zhaoti Wang; Qing Yan; Margaret A Sharp; Nicola Klein; Ann M Arvin; George Kemble
Journal:  J Infect Dis       Date:  2006-04-12       Impact factor: 5.226

9.  Protection against congenital cytomegalovirus infection and disease in guinea pigs, conferred by a purified recombinant glycoprotein B vaccine.

Authors:  Mark R Schleiss; Nigel Bourne; Greg Stroup; Fernando J Bravo; Nancy J Jensen; David I Bernstein
Journal:  J Infect Dis       Date:  2004-04-01       Impact factor: 5.226

10.  Induction of pluripotent protective immunity following immunisation with a chimeric vaccine against human cytomegalovirus.

Authors:  Jie Zhong; Michael Rist; Leanne Cooper; Corey Smith; Rajiv Khanna
Journal:  PLoS One       Date:  2008-09-22       Impact factor: 3.240

  10 in total
  4 in total

1.  Cytomegalovirus: pathogen, paradigm, and puzzle.

Authors:  Michael Boeckh; Adam P Geballe
Journal:  J Clin Invest       Date:  2011-05       Impact factor: 14.808

2.  The clinical and financial burden of pre-emptive management of cytomegalovirus disease after allogeneic stem cell transplantation-implications for preventative treatment approaches.

Authors:  Natasha A Jain; Kit Lu; Sawa Ito; Pawel Muranski; Christopher S Hourigan; Janice Haggerty; Puja D Chokshi; Catalina Ramos; Elena Cho; Lisa Cook; Richard Childs; Minoo Battiwalla; A John Barrett
Journal:  Cytotherapy       Date:  2014-05-13       Impact factor: 5.414

3.  Identification of Mouse Cytomegalovirus Resistance Loci by ENU Mutagenesis.

Authors:  Karine Crozat; Philippe Georgel
Journal:  Viruses       Date:  2009-10-20       Impact factor: 5.048

4.  High susceptibility to cytomegalovirus infection of pregnant women in Flanders, Belgium.

Authors:  E Leuridan; M Ieven; N Hens; P Van Damme
Journal:  Facts Views Vis Obgyn       Date:  2012
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.